175 related articles for article (PubMed ID: 15585396)
1. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Chandler NM; Canete JJ; Callery MP
J Gastrointest Surg; 2004 Dec; 8(8):1072-8. PubMed ID: 15585396
[TBL] [Abstract][Full Text] [Related]
2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
3. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Bold RJ; Virudachalam S; McConkey DJ
J Surg Res; 2001 Sep; 100(1):11-7. PubMed ID: 11516199
[TBL] [Abstract][Full Text] [Related]
5. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells.
Christgen M; Schniewind B; Jueschke A; Ungefroren H; Kalthoff H
Cancer Lett; 2005 Sep; 227(2):193-200. PubMed ID: 16112422
[TBL] [Abstract][Full Text] [Related]
7. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
[TBL] [Abstract][Full Text] [Related]
10. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Nabhan C; Gajria D; Krett NL; Gandhi V; Ghias K; Rosen ST
Mol Cancer Ther; 2002 Nov; 1(13):1221-7. PubMed ID: 12479703
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Märten A; Zeiss N; Serba S; Mehrle S; von Lilienfeld-Toal M; Schmidt J
Mol Cancer Ther; 2008 Nov; 7(11):3624-31. PubMed ID: 19001444
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells.
Huang XY; Wang HC; Yuan Z; Li A; He ML; Ai KX; Zheng Q; Qin HL
Acta Pharmacol Sin; 2010 Jun; 31(6):741-5. PubMed ID: 20523344
[TBL] [Abstract][Full Text] [Related]
14. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
Zhang J; Jiang H; Mao Z; Wang X; Fan X; Liu Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):335-40. PubMed ID: 25030587
[TBL] [Abstract][Full Text] [Related]
17. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
18. MSX2 overexpression inhibits gemcitabine-induced caspase-3 activity in pancreatic cancer cells.
Hamada S; Satoh K; Kimura K; Kanno A; Masamune A; Shimosegawa T
World J Gastroenterol; 2005 Nov; 11(43):6867-70. PubMed ID: 16425399
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
J Surg Res; 2003 Jul; 113(1):88-95. PubMed ID: 12943815
[TBL] [Abstract][Full Text] [Related]
20. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]